Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

PURPOSE: Patients with Ewing sarcoma (ES) with metastases and those who relapse fare poorly and receive therapies that carry significant toxicity. This phase 1/2 study was conducted to evaluate the efficacy of figitumumab in advanced ES. PATIENTS AND METHODS: Patients with sarcoma 10 to 18 years old...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Juergens, Heribert, Daw, Najat C., Geoerger, Birgit, Ferrari, Stefano, Villarroel, Milena, Aerts, Isabelle, Whelan, Jeremy, Dirksen, Uta, Hixon, Mary L., Yin, Donghua, Wang, Tao, Green, Stephanie, Paccagnella, Luisa, Gualberto, Antonio
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2011
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236653/
https://ncbi.nlm.nih.gov/pubmed/22025154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.0670
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items